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PalmitoylationCD36/FAT is a transmembrane glycoprotein that functions in the cellular uptake of long-chain fatty acids and also
as a scavenger receptor. As such it plays an important role in lipid homeostasis and, pathophysiologically, in the
progression of type 2 diabetes and atherosclerosis. CD36 expression is tightly regulated at the levels of both
transcription and translation. Here we show that its expression and location are also regulated post-
translationally, by palmitoylation. Although palmitoylation of CD36 was not required for receptor maturation
and cell surface expression, inhibition of palmitoylation either pharmacologically with cerulenin or by mutation
of the relevant cysteines delayed processing at the ER and trafﬁcking through the secretory pathway. The absence
of palmitoylation also reduced the half life of the CD36 protein. Additionally, the CD36 palmitoylationmutant did
not incorporate efﬁciently into lipid rafts, a site known to be required for its function of fatty acid uptake, and this
reduced the efﬁciency of uptake of oxidized low density lipoprotein. These ﬁndings provide an added level of
sophistication where translocation of CD36 to the plasma membrane may be physiologically regulated by
palmitoylation.University of Newcastle, NSW
16903.
Thorne).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
CD36, ﬁrst identiﬁed as a plasma membrane glycoprotein on
platelets and as a membrane component of milk fat globules, is a
versatile molecule that can bind many ligands (reviewed in [1–4]). On
macrophages and retinal epithelial cells it functions in the phagocytic
uptake of apoptotic corpses and shed photoreceptor outer segment
fragments, and it also engages in the endocytotic uptake of modiﬁed
proteins and lipids includingglycatedalbumin andoxidatively damaged
lipoproteins [5–10]. These latter functions in particular may account for
the demonstrated role of CD36 in the development of human diabetic
nephropathy [11], and, as shownbySilverstein and colleagues in a series
ofmousemodels, in thedevelopment andprogressionof atherosclerosis
[12–14]. However, studies on CD36-null mice and also with transgenic
mice demonstrated, primarily, an important role for CD36 in lipid
homeostasis, validating the earlier ﬁndings of Abumrad and colleagues
who had isolated and identiﬁed a facilitator of long chain fatty acid
(LCFA) uptake in rat adipocytes and named it FAT, for fatty-acid
translocase [15]. CD36/FAT-null mice exhibit increased fasting levels ofcholesterol, triacylglycerol and LCFA, and hypoglycaemia [16]. Con-
versely, transgenic mice overexpressing CD36 in skeletal muscle were
lean with less adipose tissue, had reduced triglycerides and LCFAs, and
signiﬁcantly elevated plasma glucose levels [17]. Substantiating these
ﬁndings in mice, the SHR/NIH spontaneously hypertensive rat which
exhibits multiple metabolic disorders similar to the human dysmeta-
bolic syndrome was found to contain a deletion variant of CD36 [18].
Numerous in vitro studies with isolated tissues, and with muscle cells,
cardiomyocytes and adipocytes have now established a direct role for
CD36 in LCFA uptake by these cell types [15,17,19–23] although the
mechanism of uptake remains to be determined. Critical to this and
perhapsother CD36-mediated functions is the localisation of the protein
to plasma membrane lipid raft domains [22].
The CD36 sequence indicates an unusual structure for this molecule.
It contains an uncleaved signal peptide at the amino terminus and a
transmembrane domain followed by a short predicted carboxyl
terminus and, in their original cloning paper, Oquendo et al. [24]
doubted that the uncleaved signal sequence was sufﬁcient to provide a
membrane anchor. Lublin and colleagues addressed this topology issue
by mutagenizing the pairs of juxtamembrane cysteines at either end of
the molecule and showing that all four were palmitoylated in human
embryonic kidney cells, indicating their cytosolic location and, thereby,
a horseshoe topology for CD36 [25]. It had been known for some time
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showing that in adipocytes CD36 was the dominant marker for
palmitoylation in adipocytes, and that this palmitoylation was greatly
increased by treatment of the cells with insulin [26]. Furthermore,
insulin also rapidly stimulates the surface expression of CD36 inmuscle
cells [27,28]. However, the functional consequences of palmitoylation of
this highly hydrophobic molecule have never been addressed. We
undertook the present study anticipating that dynamic palmitoylation
might serve to regulate CD36 function at the plasma membrane. Our
ﬁndings, however, indicate that palmitoylation of CD36 inﬂuences the
expression and location of themolecule at amore basic level, suggesting
that this post-translational modiﬁcation serves as an additional
regulator of functional expression at the cell surface.
2. Materials and methods
2.1. Cell lines, expression constructs and transfections
The WM115 and MV3 human melanoma, RD rhabdomyosarcoma
and COS-7 cell lines were maintained as described previously [29,30].
Stable transfection of MV3 cells was performed by co-transfection
with pREP9 and either pEF.BOS empty vector (MV3.BOS) or pEF.BOS
containing wildtype CD36 cDNA (MV3.CD36) or the non-palmitoy-
lated AA-SS mutant (MV3.AA-SS) described in Thorne et al. [30,31].
Transient transfections were performed by electroporation as previ-
ously described [31].
2.2. Antibodies
Monoclonal antibodies (mAb) against CD36 (VM58, 11H5, Mo25
and Long 9), control anti-human μ-chain mAb (HB57), FMC-56 anti-
CD9 mAb, anti-DAF mAb, afﬁnity puriﬁed polyclonal antibodies
against CD36 and β1-integrin, polyclonal anti-caveolin-1 and poly-
clonal anti-calreticulin have been described previously [29,30,32–34].
Antibodies against calnexin and the Golgi SNARE protein Vti1a were
purchased from (Transduction Labs, Lexington, KY).
2.3. Flow cytometry and immunoﬂuorescence microscopy
Surfaceantigenexpression analysiswasperformedon trypsin-versene
harvested cell suspensions as previously described [30]. Immunoﬂuores-
cence microscopy was performed as previously described on cells
attached to glass coverslips [34].
2.4. In vivo cell labeling
For labeling experiments with palmitate, cell monolayers were
rinsed with DMEM supplemented with 10 mg/ml fatty acid free (FAF)
BSA (ICN Biomedicals) and then pre-incubated in the FAF-media for
30 min at 37 °C. Thismediumwas then removedand replacedwith FAF-
medium containing either 1 mCi/ml 35S-methionine/cysteine or 3H-
palmitic acid (DuPont-NEN). To concentrate the palmitate label from
the ethanol stock solutions, each was dried under vacuum and
redissolved in DMSO before adding to labelling medium at a ﬁnal
DMSO concentration of 0.3% (v/v). The cells were lysed and immuno-
precipitations performed as previously described [31]. Incorporation of
the radiolabelwas assessed byﬂuorographyusing Amplify (Amersham)
after SDS-PAGE. Pulse-chase labeling experiments with 35S-methio-
nine/ cysteine were conducted as previously described [33].
2.5. Streptavidin capture of surface biotinylated proteins
Cell surface antigens were ﬁrst labelled with biotinamidocaproate N-
hydroxysuccinimide ester (Sigma) as described previously [30]. Soluble
cell lysates were then prepared and adsorbed to streptavidin-coupled
agarose beads (Sigma). The beads were then extensively washed withhigh salt RIPA buffer before elution of the beads with sample buffer.
Following resolution by SDS-PAGE and transfer to nitrocellulose,
immunoblotting was performed [34].
2.6. Subcellular fractionations
Analyses were performed by ultracentrifugation using gradients of
iodixanol (Optiprep, Axis-Shield). Cell suspensions in HB (0.25 M
sucrose, 1 mMEDTA, 20 mMHepes-NaOH, pH 7.4) containing protease
inhibitors (Roche) prepared from 360 to 540 cm2 cultures were
homogenised by nitrogen cavitation in a Parr 45 mL cell disruption
bomb (550 psi, 15 min; Parr Instruments). Cell nuclei and heavy
organelles were removed from the homogenate by sequential centri-
fugation at 1000g and 10,000g, respectively, before preparation of a
100,000g membrane pellet (P100). This material was thoroughly
resuspended in HB before being overlaid onto a pre-formed linear 10–
30% of Optiprep prepared in HB before centrifugation for 2 h at
100000×g in an SW41Ti rotor (Beckman-Coulter). Fifteen equal
fractions were collected from the bottom of each tube.Where indicated
the immunoprecipitates were digested with endoglycosidase H accord-
ing to the manufacturer's instructions (New England Biolabs).
2.7. Isolation and analysis of detergent-resistant membranes
DRMs were prepared by ﬂoatation on sucrose density gradients by
ultracentrifugation of Triton X-100 lysates as previously described
[30,31]. Fractions were collected from the top of the gradient and equal
protein amounts from each fraction were analysed by immunoblotting.
In some experiments the partitioning of CD36 to the DRM and other
fractions was determined using densitometric analysis using Multi-
Guage software (Fuji Imaging). Statistical analysis was performed using
the Student's t-test.
2.8. Bivariate analysis of oxLDL uptake
DiI (1,1'-diotadecyl-3-3-3'-3'-tetramethyllindocarbocyanine
percholorate) labeled oxLDL was purchased from Intracel Corporation
(Rockville, MD) and incubated with the MV3 cells as indicated. Cells
were then harvested with trypsin-versene solution, immunostained
on ice with VM58-FITC (anti-CD36) before data acquisition using a
FACScan ﬂow cytometer (Becton-Dickinson) using the FL2 or FL1
emission ﬁlters for DiI and FITC, respectively. In some assays human
transferrin uptake (Sigma; labelled with FITC isomer 1 (Calbiochem))
was compared with CD36 levels detected with an anti-mouse PE
conjugate. The data were exported and analysed using the bivariate
spreadsheet method as reported previously [35].
Brieﬂy, all cell event data are categorised according to the levels of
expression of receptor (CD36). After excluding channels with zero or
low frequency of cell events, the average ﬂuorescence values for (DiI-
oxLDLor transferrin) liganduptakeare calculated for each receptor level
category and the results plotted. To compare samples, the spreadsheet
incorporates a Student's t-test that compares the uptake of ligand for
receptor categories displaying equivalent receptor expression.
3. Results
3.1. A non-palmitoylated AA-SS mutant of CD36 is expressed at the
plasma membrane in the correct conformation
CD36 has been demonstrated previously to be palmitoylated on a
pair of cysteines at either end of the molecule, adjacent to putative
transmembrane domains [25]. To conﬁrm that these cysteines
accounted for the total palmitoylation of CD36, we prepared amutation
in which the cysteine pair toward the aminoterminus were substituted
with alanines, and those towards the carboxyl terminus with serines
(AA-SS mutation; Fig 1A). Constructs were then transfected into COS-7
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transfection thus permitting reasonable ﬂuorography timeswhen using
fatty acids labelled with weak β-emitting isotopes. Two days following
transfection, a proportion of the cells were stained for CD36 by ﬂow
cytometry and these analyses revealed comparable levels of surface
expressed protein for each transfected product (Fig 1B).
The remaining cells were equally divided then metabolically
labelled with 35S-cysteine/methionine as a measure of total protein,
or with 3H-palmitic acid to measure palmitoylation. The cells were
lysed and immunoprecipitated for CD36 and, sequentially, for CD9, a
molecule endogenously expressed by COS-7 cells and known to be
palmitoylated [36]. Immunoprecipitates were resolved by SDS-PAGE
and labelled proteins determined by ﬂuorography. As shown in Fig. 1C
the Cys/Met labelling of the internal control, CD9, indicating
equivalent levels of protein expression. As anticipated from the
work of Tao et al. [25], the palmitate label was incorporated into wtFig. 1. Analysis of CD36 acylation. (A) Schematic representation of CD36 showing the
hydrophobic transmembrane domains (black boxes) and the amino- and carboxylterm-
inal peptide sequences. A mutant construct was made where the cysteine residues at the
aminoterminus (3,7) and the carboxylterminus (464,466) weremutated to either alanine
or serine, respectively (AA-SS). (B) COS-7 cells were transiently transfected with either
wildtypeCD36or theAA-SSmutant and twodays following transfection cellswere stained
on the surface with a control (HB57; open proﬁle) or an anti-CD36 mAb (VM58; black
proﬁle) and then analysed byﬂowcytometry. (C) The remaining cells fromBwere divided
equally, and metabolically labelled for 4 h with 35S-cysteine/ methionine (Cyst/Meth)
or 3H-palmitic acid (Palmitate) and cell lysates subjected to immunoprecipitation (i.p.)
with an anti-CD36 mAb cocktail (VM58, IA7, IE8) and then sequentially with an anti-CD9
mAb (FMC56). The immunoprecipitates were electrophoresed using 7.5% SDS-PAGE
under reducing conditions andﬂuorography performed for 4 h (Cys/Meth), 1 week (CD9;
Palmitate), 5.5 weeks (CD36; Palmitate).CD36 but not into the AA-SS mutant, and this work together with our
analysis of a panel of cysteine-substitution mutants (data not shown)
conﬁrmed that the four cytoplasmic cysteine residues account for the
entire palmitoylation of CD36.
We then measured the expression and conformation of the AA-SS
mutant in more physiologically relevant cells. In vivo, most melanoma
and muscle tissues express CD36 [37,38] therefore we selected the
MV3 melanoma cell line and the RD rhabdomyosarcoma cell lines for
our transfection experiments since they lack endogenous CD36
expression although other cultured melanoma cell lines as well as
other isolates of RD cells do display high levels of endogenous CD36
([30]; data not shown). TheMV3 cells were stably transfected with wt
CD36 and the AA-SS constructs and after selection in G418, the surface
expression of CD36 was analysed with a conformational dependent
mAb (VM58) that identiﬁes only the correctly foldedmaturemolecule
[33]. However, a difference in cell surface expression of CD36 was
found between the AA-SS and wt expressing cells in that–in order to
achieve comparably high levels of surface expression to the wt CD36-
expressing cells–the AA-SS-expressing cells had to be enriched for
high expression by several rounds of ﬂuorescence-activated cell
sorting. Thus although able to achieve high levels of surface
expression, this ﬁnding suggests that the expression of the AA-SS
mutant may be less stable than that of wtCD36 in the transfected MV3
cells. After such selection, however, as shown in Fig. 2 and in data not
shown, whether analysed by ﬂow cytometry (Fig. 2A) or immuno-
ﬂuorescent microscopy (Fig. 2B) using antibodies that recognise the
mature CD36 conformation, the wt and AA-SS transfected MV3 cells
expressed equivalent CD36 protein at the cell surface. An independent
method, biotinylation of the cell surface (Fig. 2C) conﬁrmed these
results with the only difference noted being a slight reduction in
electrophoretic mobility of the AA-SS relative to wt CD36 protein.
3.2. Palmitoylation is required for efﬁcient processing and ER to Golgi
trafﬁcking of CD36
Next we examined the synthesis and glycosylation of the AASS
mutation of CD36 using pulse-chase analysis. Alessio et al. [39] have
carried out a detailed analysis of the synthesis, processing and
intracellular transport of CD36 in monocytic cell lines, and these
authors established the precursor relationships of a 74 kDa species
thatmatures to the largermolecule found on the cell surface; however
they also noted that the rate of processing could vary signiﬁcantly
between different cell lines. For this reason we ﬁrst assessed the
synthesis and processing of the endogenous CD36 in WM115
melanoma cells in pulse-chase analyses. The results demonstrated
the expected precursor CD36 product(s) converting to the mature
protein during the chase period, with the half life of the precursor
protein found to be around 120 min (Fig. 3A). We then compared the
rate of conversion in MV3 cells stably expressing wt CD36 or the AA-
SS mutant. The results illustrated in Fig. 3B show that the rate of
conversion from the precursor to the mature CD36 molecule was
substantially the same as the endogenous protein in MV3 cells
expressing wt CD36 (at around 90 min for 50% conversion); however
this process was considerably slowed in cells expressing the AA-SS
mutant. In these cells normal processing did occur, but the appearance
of the mature molecule was substantially delayed such that the time
required for 50% conversion of the precursor was extended to around
4 h (Fig. 3B). Very similar results were obtained with transiently
transfected RD cells where the appearance of the mature band also
was delayed by 1–2 h in the AA-SS expressing cells (Suppl. Fig. 1).
These results suggest that palmitoylation of CD36 is required for
efﬁcient conversion of the CD36 precursor into thematuremolecule. This
notion was substantiated by immunoblotting of whole cell lysates from
the stably transfectedMV3melanoma cells when the precursor bandwas
seen clearly to accumulate in the AA-SS-expressing cells but not in those
expressing wt CD36 (Fig. 3C). Moreover, the persistent band was not
Fig. 2.Wild-type CD36 and the AA-SSmutation of CD36 are expressed on the surface ofMV3melanoma cells. (A)MV3 cellswere permanently transfectedwith control vectors (BOS),wt CD36
(CD36) or the AA-SSmutantwere analysed for surface expression of CD36 as described in Fig. 1. (B) Indirect immunoﬂuorescent staining of non-permeabilizedMV3melanoma cells. Shown are
optical sections through the cells, towards the basolateral sidewith thenuclei counterstainedwithDAPI (blue) of vector-only (BOS),wt CD36or theAA-SSmutant transfected cells. (C) TheMV3
transfectants were labeled on the surface with biotin, lysed and surface proteins adsorbed to streptavidin agarose. After electrophoresis samples were ﬁrst blotted with the anti-CD36 pAb and
then a β1-integrin pAb as a loading control. All results were reproduced in at least 3 independent experiments.
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entirely consistent with the interpretation that this represents
the ~74 kDa CD36 precursor. However, there is a polymorphism of
CD36, a proline to serine substitution at position 90, which results in the
failureof expressionat the cell surfaceof somecell types, and thishasbeen
attributed to a folding defect causing the precursor protein to be retained
in the ER [40]. In addition, we have found that a number of other
mutations to CD36 cause a similar folding defect in MV3 cells (data not
shown), therefore it was important to establish that the failure of
maturation of the AA-SS mutation is a consequence of the absence of
palmitoylation and not of the mutations themselves. To test this
pharmacologically we used the mycotoxin, cerulenin, since this natural
antibiotic has been shown previously to block palmitoylation of CD36 in
rat adipocytes [41]. After treatment of theMV3 cells stably expressing wt
CD36 with cerulenin at a non-toxic dose (5 μg/ml; Suppl. Fig. 2), it was
foundbyWestern blotting that this similarly resulted in the appearance of
the lower, precursor band in a dose-dependent manner (Fig. 3D). The
reduction in electrophoretic mobility infers that palmitoylation of CD36
had been partially inhibited by cerulenin, and taken together with the
results obtained with the AA-SS mutational analysis showing the
persistence of the CD36 precursor molecule, it can be concluded that
palmitoylation of CD36 is important for the efﬁcient maturation of the
mature cell surface expressed molecule.
Although the 74 kDa band has been established as a precursor of the
mature protein in pulse-chase experiments (Fig. 3) [39], the location and
nature of this molecule has not been examined previously. To begin this
process we prepared total membranes from stable MV3 transfectants by
nitrogen cavitation and further separated these on Optiprep gradients to
differentially separate ER, Golgi and plasma membranes. Individual
fractions collected from both the wt CD36 and AA-SS expressing cells
were thenblotted for calnexin as amarker for the ER,withVTi1a as aGolgimarker, and alsowith amAb against CD36 (Fig. 4A). The results show that
whereas wt CD36 is distributed across the gradient, the location of the
precursorbandseen in theAA-SSmutant is largely coincidentwith theER-
enriched fractions. Further evidence for the ER location of this precursor
band was obtained by treating similar fractions with endoglycosidase
(Endo)H before analysis: this enzyme cleaves only high mannose sugars
before they are processed in the medial Golgi and, thus, sensitivity to
cleavage generally indicates an ER localisation. In these experiments
(Fig. 4B and C) a low proportion (~10%) of the wt CD36 located in the
fractions containing ER membranes was subject to EndoH cleavage. In
contrast, samples from the AA-SS expressing cells showed a much high
degree of sensitivity to EndoH-treatment, indicated by the prominent
appearance of a band at ~53 kDa that corresponds to the size of the core
CD36 protein (Fig 4B). Also evident in Fig. 4B is the almost complete
disappearance of the precursor band in the EndoH treated samples, a
result consistent with the entire precursor band being digested by this
enzyme. These results show that the CD36 precursor that persists in the
AA-SS mutant has failed to reach the medial Golgi for further processing
and is likely retainedat theER. The results also established that the smaller
size of the precursor is caused by a difference in glycosylation, because the
largerEndoH-sensitive formand the smallerprecursorbothmigrate to the
same Mr after EndoH treatment.
3.3. Palmitoylation is required for efﬁcient incorporation into
membrane rafts
CD36 was one of the ﬁrst membrane proteins shown to locate to
plasma membrane rafts in endothelial cells [42], identiﬁed biochemi-
cally as detergent resistant membranes, DRMs [43], and subsequently a
raft localization for CD36 has been shown in several cell types
[30,31,44]. We carried out similar DRM analysis of wt CD36 and AA-SS
Fig. 3. Inﬂuence of palmitoylation on the biosynthetic processing of CD36. (A) Pulse chase analyses of WM115 human melanoma cells which endogenously express CD36. The cells
were pulse labeled with 35S-cysteine/methionine for 30 min and chased for the indicated periods (min). Immunoprecipitations were performedwith an anti-CD36 antibody cocktail
and the samples analysed by ﬂuorography following reducing conditions of SDS-PAGE. The black arrowhead indicates fully glycosylated mature CD36 (M), the open arrowhead the
precursor bands (P). Densitometric analysis at right shows the kinetics of conversion of the CD36 precursor to the mature form. (B) Comparison of the biosynthetic processing of
wildtype CD36 with the AA-SS mutant in MV3 melanoma cells conducted as for (A) Similar data were obtained in two experiments. (C) Soluble cell lysates from permanent
transfectants of MV3 cells expressing the empty vector (BOS), CD36 or AA-SS were immunoblotted for CD36. (D) MV3 permanent transfectants of wt CD36 from were treated for
16 h with 5 μg/ml cerulenin before the preparation of cell lysates. The pattern of electrophoretic mobility of wtCD36 was compared to the AA-SS mutant protein using
immunoblotting against CD36. The increased mobility of wtCD36 suggests that palmitoylation had been partially inhibited by cerulenin. Data in (C) and (D) were reproduced on at
least three occasions.
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by palmitoylation. First, we established that endogenous CD36
expressed by melanoma cells was enriched in DRM fractions upon
sucrose gradient analysis, and thiswas shown to be the case forWM115
melanoma cells (Fig. 5A). Examination of the transfected MV3 cells in
the sameway showedwt CD36 to be highly enriched within the visible
ﬂoating band that also contained caveolin (Fig. 5B and Suppl. Fig. 3)
consistent with our previous analysis [30]. By contrast, the AA-SS
protein was less evident within the DRM fractions and was most
strongly expressed in fraction 6, a position on the gradient that was
intermediate between the DRM fractions and the soluble fractions
(Fig. 5B). Both wt and AA-SS showed only trace amounts across the
soluble fractions that contained the ER protein, calreticulin. Densito-metric analysis of multiple isolations conﬁrmed the altered distribution
of the AA-SS to the intermediate fraction to be a consistent statistically
signiﬁcant ﬁnding (Fig. 5C). Very similar results were obtained using
transiently transfected RD cells that displayed strong enrichment of the
AA-SS protein to intermediate density fractions (Fig. 5D).
To ensure that these results were a direct consequence of the loss of
palmitoylation andnot the effects of the substitutionmutations in theAA-
SS protein, we again employed pharmacologic inhibition of palmitoyla-
tion. Treatment of the MV3.CD36 cells with cerulenin showed a modest
but signiﬁcant reduction in theamountof CD36protein localising toDRMs
when normalised against DAF, a GPI-linked (i.e. non-palmitoylated)
protein known to isolate to DRMs (Fig. 5E). Due to the toxicity limitations
of treating MV3 cells with cerulenin (Suppl. Fig. 2) and its partial
Fig. 4. Fractionation of cellular organelles reveals the AA-SS precursor molecule is associated with the ER. (A) MV3.CD36 and MV3.AA-SS cells were disrupted by nitrogen cavitation
and the P100 membrane fraction was applied to 10–30% Optiprep gradients that were processed by ultracentrifugation. Fractions were collected from the bottom of each tube and
equal volumes applied to SDS-PAGE gels. After transfer to nitrocellulose these membranes were immunoblotted for either calnexin, VTi1a or CD36. (B) Samples from (A) were
digested with endoglycosidase H (endoH) before immunoblotting for CD36. Asterisk at ~53 kDa denotes the core (de-glycosylated) CD36 molecule. (C) Densitometric analysis of
(B) showing that the percentage of endoH-resistant (mature) protein across the gradient is substantially decreased for the AA-SS protein relative to wt CD36.
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the palmitoyl-modiﬁcation of CD36 is required for efﬁcient incorporation
into membrane raft domains.
3.4. Palmitoylation inﬂuences the uptake of lipids from oxidised low
density lipoprotein by CD36
As described in Introduction, the localisation of CD36 to DRMs has
known functional consequenceswith respect to the uptake of FA [22]. In
previous we work we have established that CD36 transfection of MV3
cells was sufﬁcient to elicit enhanced uptake of lipids from oxidatively
damaged lipoproteins [10]. Microscopic examination of the uptake
oxLDL showed that the AA-SS receptors were not functionally deﬁcient
since these transfectants took upmuchmore oxLDL than control vector-
transfected cells. Although both the CD36 and AA-SS transfected MV3
cellswere able touptakeDiI-labelledoxLDLwitha similar distributionof
the DiI within cytoplasmic vesicles, some MV3.AA-SS cells appeared to
uptake lessﬂuorophore (Fig. 6A).We therefore sought to investigate the
effect of palmitoylation on CD36 function by examining the uptake of
oxLDL in a quantitative assay.
For this we applied a bivariate ﬂow cytometric assay, a technique
developed to overcome the bias of differences in receptor expression in
cell based ligandbindingassays [35].MV3-CD36andAA-SScellswerepre-
loadedwith 1- 25 μg/mlDiI-labelled oxLDL before transferring the cells to
ice and staining for CD36 expression using a mAb directly coupled to
ﬂuorophore. Flow cytometry was performed and the data analysed using
the bivariate method (Fig. 6B). There was a signiﬁcant decrease in the
uptake of lipids as reported by the DiI lipid analogue in the AA-SS cells
relative towt CD36 evaluated across the range of CD36 surface expression
levels, with increasing differences between wt CD36 and AA-SS with
increasing ligand loading (Student's t-test, Fig. 6B(i)–(v)). As further
validation of this assay we undertook a comparison of theMV3.CD36 and
AA-SS cells using transferrin uptake. Transferrin is readily taken up by
MV3 cells but in this capacity serves as a control ligand whose receptor
system is independent of CD36 function. There were little differences
betweenCD36andAA-SS expressing cells in this assay (Fig. 6B(vi)). Takentogether these results showthat thepalmitoylationof CD36 inﬂuences the
efﬁciency of uptake of oxLDL, possible in consequence of its role in
targeting the molecule to plasma membrane rafts.
4. Discussion
In this study we demonstrate themultifaceted effects of palmitoyla-
tion on the transmembrane glycoprotein, CD36/FAT and suggest these
provide a novel regulatory function. We show that in the absence of
palmitoylation in melanoma cells and rhabdomyosarcoma cells, post-
translational processing is considerably delayed at the ER. Additionally
we determine that in the absence of palmitoylation CD36 is also poorly
incorporated into plasmamembrane rafts and, perhaps in consequence,
displays reduced efﬁciency of uptake of its ligand, oxLDL. Therefore
our results suggest that, in the context of CD36, palmitoylation provides
several mechanisms of control, both the efﬁciency of receptor matu-
ration, the correct localisation at the plasmamembrane and the uptake
of ligand. Such ﬁndings point to possible aspects important to the
physiological functioning of CD36.
It has been known since the work of Jochen and Hays over a decade
ago that CD36 is the major substrate for palmitoylation in adipocytes,
and that this palmitoylation was increased by insulin stimulation and
inhibited by cerulenin [26,41]. Also treatment of adipocytes with
cerulenin inhibits surface expression of CD36 [45], results consistent
with our data showing that the inhibition of acylation by cerulenin
inhibits the maturation state of CD36. Moreover, abrogation of
palmitoylation by mutation resulted in the accumulation of the CD36
precursor molecule in the endoplasmic reticulum. Similar ﬁndings of a
requirement for palmitoylation for proper intracellular sorting and
forward transport have been obtained by Berthiaume and colleagues in
their studies of apolipoprotein B [46,47]. These authors suggest that the
levels of palmitoyl-CoA, the substrate for palmitoyltransferases (PAT)
enzymes, may act as a molecular sensor for the availability of newly
synthesised neutral lipids, thereby coordinating this with secretion.
Since CD36 is a major receptor in the uptake of LCFA that subsequently
can also be utilized by PAT enzymes, an attractive hypothesis is that
Fig. 5. Mutation of all palmitoylated cysteines in CD36 results in distribution out of DRMs. (A) Triton X-100 lysates prepared from the WM115 human melanoma cell line (that
endogenously expresses CD36) were subjected to sucrose density fractionation by ultracentrifugation. Equal protein amounts from each fraction were analyzed by western blot
analysis with both CD36 and caveolin pAbs. CD36 was highly enriched within the DRM-fractions 3 and 4 also containing the marker protein caveolin. (B) Analysis of CD36 or the AA-
SS expressing MV3 cells as described for (A) revealed wildtype CD36 to be enriched with caveolin whereas the AA-SS mutant was observed to be concentrated in a higher density
fraction (fraction 6) intermediate between caveolin-enriched DRMs and the Triton X-100 soluble fractions shown by the calreticulin marker. (C) Densitometric analysis of anti-CD36
western blots showing the percentage of CD36 present in the DRM fractions (D; 1–5), intermediate fraction (I; 6) and soluble fractions (S; 7–12). These data were pooled from 9
independent experiments (6 wt and 3 AA-SS) all giving results similar to those shown in (B) above. The error bars are standard deviations. (D) The analysis detailed in (B) was
repeated on RD cells transiently transfected with wt CD36 or AA-SS. (E) MV3.CD36 cells were subjected to 16-h incubation with ethanol carrier (control) or 5 μg/ml cerulenin before
preparing DRMs. Densitometric analysis after Western blot determination of CD36 and DAF (a GPI-linked protein found in DRMs) showed that cerulenin treatment signiﬁcantly
reduces the amount of CD36 protein in DRMs after normalisation against DAF protein levels (n=4). The error bars are standard error of the mean.
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tion to reduce these levels by endocytosis. Berthiaume and colleagues
also suggest that the palmitoylation of apoB serves to localize it to
subcompartments of the ER rich in neutral lipids. It is possible that CD36
accumulates in such subcompartments of the ER, directed by palmitoy-
lation, and that these sub-compartments are then targeted together to
the Golgi regions believed to be involved in raft formation [48].
Interestingly,wenoted that in the absenceof palmitoylationCD36was
enriched in intermediate density fraction(s) of the sucrose gradients
(Fig. 5). The origin of this region is not known but preliminary blotting
experiments across the gradient from lysates of transfected MV3 cells
labeled on the surface with biotin indicate that they represent internal
rather than surface material (Suppl. Fig. 4A), and these fractions are also
relatively enriched in GS28 (a Golgi marker; Suppl. Fig. 4C). The Golgi
apparatus is thought to represent the site of lipid raft formation [48] but
the intracellular pool of FAT/CD36 from ﬁbroblasts that fractionates with
the Golgi was reported to not be associated with lipid rafts [22]. Such a
mechanism would be consistent with our ﬁndings that in the absence of
palmitoylation, forward trafﬁcking and maturation of the AA-SS mutant
through the secretorypathway is retarded, andperhaps in consequence of
this, the mutant CD36 protein fails to efﬁciently localize to raft domains.
We previously determined that the tetraspanins CD9 and CD63, alsosubject to extensivemodiﬁcation by palmitoylation,were also enriched in
intermediate density fractions [30] but it will require further analysis to
establish whether this biochemical localisation truly represents the Golgi
or some other physiological compartment.
Our results also infer that that CD36 is most likely palmitoylated at
the ER as evidenced by the subcellular fractionation studies presented
in Fig. 4. The substrate speciﬁcity of the large family of mammalian
PAT enzymes are poorly understood, but in yeast, Swf1, a member of
the DHHC-CDR family PATs, has been identiﬁed as being responsible
for the palmitoylation of most transmembrane proteins that are
modiﬁed at cysteine residues close to the cytoplasmic end of the
transmembrane domain [49]. Swf1 is localized at the ER, and a dele-
tion mutation of this enzyme–resulting in a failure of palmitoylation–
causes the substrate TM containing proteins to be ubiquitinated, mis-
sorted and degraded. In our experimental system we have driven
CD36 expression with a powerful EF promoter enabling high levels of
expression in the absence of the normal regulators and, together with
selection by cell sorting, this was sufﬁcient to drive high cell-surface
expression of the AA-SS mutant in melanoma cells. However,
comparative examination of these cells after cycloheximide treatment
was able to conﬁrm that the half life of the AA-SS proteinwas less than
wt CD36 (Suppl. Fig. 5) supporting the notion that in the absence of
Fig. 6. Palmitoylation of CD36 is required for efﬁcient uptake of oxLDL in transfectedMV3melanoma cells. (A) MV3melanoma cells permanently transfected with the control vector (BOS) or
wildtype CD36 or the palmitoylation mutant (AA-SS) were allowed to attach to glass coverslips before treatment with 5 μg/ml of DiI-labelled-oxLDL for 3 h. After incubation the cells were
washed, ﬁxed and prepared for examination by epiﬂuorescent microscopy. As shown, the micrographs contrast the paucity of accumulation of oxidised LDL in controls relative to the CD36
transfected cells. CD36 and AA-SS transfected cells displayed a similar phenotype with both perinuclear and peripheral vesicles (arrowhead) labelled with DiI. (B) Bivariate ﬂow cytometric
analysis of MV3.CD36 and MV3.AA-SS populations according to the method of Tzircotis et al. [35]. (i–v) Cells were incubated with 1–25 μg/ml DiI-OxLDL as indicated for 3 h at 37 °C and
counterstained with VM58-FITC for CD36 cell surface expression before analysis. The data shown are representative of those obtained on 3 separate occasions. (vi) Uptake assay using FITC-
labeled transferrin (25 μg/ml for 30 min at 37 °C) inMV3.CD36 and AA-SS cells. Transferrin is a ligand readily taken up byMV3 cells but whose uptake is irrelevant to the function of CD36. The
black points plotted across the abscissa ﬂag signiﬁcant differences in ligand uptake values occurring between MV3.CD36 and MV3.AA-SS cells displaying equivalent CD36 expression levels
(Student's t-tests reaching the 99.9% conﬁdencevalue). For the transferrin assays therewere fewsigniﬁcant differences betweenCD36andAA-SS expressing cell populations in two independent
assays (only 9 of 800 ﬂuorescence channels reaching signiﬁcance) compared to the results observed for the DiI-oxLDL experiments where a dose dependent response was observed.
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possibly consistent with the regulatorymechanism deﬁned by Swf1 in
yeast. Whether the AA-SS protein is subject to proteosome degrada-
tion or other mechanisms (e.g. lysosomal degradation) is not known
but our ﬁndings nevertheless support the general concept that
palmitoylation of CD36 imparts regulatory effects regarding its
incorporation into the secretory pathway.
Our secondmain ﬁndingwas that palmitoylationwas substantially
required for the enrichment of CD36 into DRMs representing plasma
membrane rafts. This property has long been established for the
membrane targeting of soluble proteins: for example, in p59fyn dual
acylation with myristate and palmitate was necessary for targeting
into DRMs [50]. However, the DRM targeting role of acylation for
transmembrane proteins such as CD36 are not so well deﬁned or
predictable given the great variety of topological subclasses of
membrane proteins and indeed their extent of acylation. For example
while palmitoylation of the transmembrane proteins α6β4 integrin
and CD4, imparts partitioning to DRMs/rafts [51–53], there are other
examples where this modiﬁcation is not sufﬁcient for targeting, e.g.
LMP2A and claudin [54,55]. Whilst the palmitoylation of CD36 has
been recorded [25], to our knowledge this targetingmechanism(s) for
incorporation to DRMs has not been previously reported for CD36 or
any of members of its gene family.
The absence of palmitoylation of CD36 also had functional conse-
quences in the reduced efﬁciency of uptake of oxLDL; this was an
expected ﬁnding since other workers have demonstrated that the
function of CD36 in the uptake of long-chain fatty acids depends upon
its localization to plasmamembrane rafts and, indeed, the binding of a
FA-analogue to CD36 at the plasma membrane occurred only within
DRMs [22]. Our ﬁndings suggest that CD36 requires a similar
localisation for the efﬁcient uptake of oxLDL. This requirement for
localisation to DRMs for efﬁcient oxLDL uptake may in part reﬂect the
conformation of CD36 in this lipid-rich environment. Previous studies
have shown that mutation of the carboxylterminal cysteines, either
singly or as a pair, was unable to inhibit the CD36-dependent uptake
of oxLDL whereas carboxylterminal truncation mutants displayed
decreased efﬁciency [56]. Additionally, Eyre and colleagues reported
that truncation of the carboxylterminal domain, inclusive of two of
the four palmitoylated cysteines, did not inﬂuence the enrichment to
DRMs but did prevent CD36-mediated FA uptake [21]. While our own
data (Fig. 1C and data not shown) and that of others [25] have shown
that mutation of all four cysteines (2 aminoterminal and 2
carboxylterminal) are necessary to abrogate palmitoylation of CD36,
our analysis of truncated CD36 constructs similar to those used in
these reported studies found that these mutations do not abrogate
palmitoylation (data not shown).
How then might our ﬁndings contribute to the better understand-
ing of the physiological regulation and function of CD36? CD36
expression is known to be regulated at the transcriptional level by
PPARγ and by the pregnane X receptor (PXR) [57,58], important
regulators of lipid homeostasis. In turn, translation of CD36 mRNA is
regulated by the availability of glucose [59]. Other important
molecules engaged in lipid homeostasis are also regulated by
PPARγ, and the levels of PPARγ and insulin as well as CD36 are
regulated by glucose [59–61]. Thus an interconnected series of
regulators coordinate the expression of different components in-
volved in lipid homeostasis. Our results suggest that in addition to the
currently known transcriptional and translational regulatory mechan-
isms, the palmitoylation requirement for functional CD36 expression
represents an additional element of ﬁne tuning.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.bbamcr.2010.07.002.References
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